SCHEMBL395600

SCHEMBL395600

CCOC(=O)c1cccc(S(=O)(=O)Nc2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.61
LMNA P02545 5/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
GAA P10253 1/20 0.57
NPSR1 Q6W5P4 4/20 0.57
HSD17B2 P37059 1/20 0.54
NHERF1 O14745 1/20 0.53
NR3C1 P04150 1/20 0.52
PGR P06401 1/20 0.52
AR P10275 1/20 0.52
ESR2 Q92731 1/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 3/20 0.52
ALOX15 P16050 2/20 0.52
MAPK1 P28482 2/20 0.52
HSD17B10 Q99714 2/20 0.52
HPGD P15428 1/20 0.52
MAPT P10636 3/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396095 0.82 AKR1C3 (0.62) LMNAGAANPSR1NR3C1PGR
SCHEMBL2828302 0.81 SMN1; SMN2 (0.61) HIF1ALMNASMN1; SMN2GAANPSR1
SCHEMBL399284 0.81 LMNA (0.64) HIF1ALMNASMN1; SMN2GAAAR
SCHEMBL17978539 0.81 NPSR1 (0.56) HIF1ALMNASMN1; SMN2GAANPSR1
SCHEMBL7578595 0.81 NPSR1 (0.72) HIF1ALMNAGAANPSR1HSD17B2
SCHEMBL14408128 0.80 GAA (0.58) LMNAGAANPSR1HSD17B2NR3C1
SCHEMBL30786693 0.80 CES2 (0.61) LMNANPSR1MEN1KMT2AALDH1A1
SCHEMBL1994068 0.80 CES2 (0.61) LMNANPSR1MEN1KMT2AALDH1A1
SCHEMBL399002 0.80 LMNA (0.55) LMNASMN1; SMN2NPSR1NHERF1AR
SCHEMBL3627604 0.80 RAB9A (0.58) LMNASMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382191-B1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE BAHAMAS LTD (BS) 2014-11-12 EP disclosed
US-8741899-B2 (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof ABBVIE INC. (US) 2014-06-03 US disclosed
US-8404719-B2 Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers ABBVIE INC. (US) 2013-03-26 US disclosed
US-20120083499-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2012-04-05 US disclosed
US-8101614-B2 Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-01-24 US disclosed
EP-2382191-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS Abbott Laboratories, Inc. (US) 2011-11-02 EP disclosed
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-08-05 US disclosed
WO-2010083264-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083499-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 HIF1A 2530/4885LMNA 868/4885SMN1; SMN2 973/4885
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 HIF1A 2530/4885LMNA 868/4885SMN1; SMN2 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.